| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 04/22/2004 | US20040077670 Novel sulfamides and their use as endothelin receptor antagonists |
| 04/22/2004 | US20040077667 Quinazolinone derivatives |
| 04/22/2004 | US20040077663 Thienopyrimidine-based inhibitors of the src family |
| 04/22/2004 | US20040077656 Quinolines and nitrogenated derivatives thereof substituted in 4-position by a piperazine-containing moiety and their use as antibacterial agents |
| 04/22/2004 | US20040077655 Piperazine derivatives for treatment of bacterial infections |
| 04/22/2004 | US20040077642 Pyrimidine compounds |
| 04/22/2004 | US20040077639 Administering amidine derivative as antiasthmatic agents; chronic obstructive pulmonary disease treatment |
| 04/22/2004 | US20040077633 N-Heterocyclic derivatives; picornavirus infections in mammals; human rhinovirus |
| 04/22/2004 | US20040077632 Pharmaceutically active hydrophilic sulfonamide derivatives as inhibitors of protein junkinases |
| 04/22/2004 | US20040077626 In vivo stability; very low metabolism rate |
| 04/22/2004 | US20040077622 penicillins and oxapenicillins with a fused bicyclic N-heteroarymethylene group; 6-[(5-benzyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)methylene]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; antibiotic resistance is reduced when administered alone or with other B-lactam antibiotics |
| 04/22/2004 | US20040077612 Acting as prodrugs; higher concentration delivery of active material to target cell in hybrid form; decreasing side effects |
| 04/22/2004 | US20040077610 Medicament containing a polyamine as an active substance |
| 04/22/2004 | US20040077600 Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease |
| 04/22/2004 | US20040077587 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| 04/22/2004 | US20040077577 Gene therapy; vaccines; inducing antibodies and/or cytotoxic or helper T lymphocytes |
| 04/22/2004 | US20040077558 9A-n-[n'-(phenylsulfonyl)carbamoyl] derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin a and of 5-o-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythronolide a |
| 04/22/2004 | US20040077557 Systemic or topical bacterial infections; erythromycin A derivatives |
| 04/22/2004 | US20040077551 NS3 protease inhibitors; quinoline derivatives |
| 04/22/2004 | US20040077534 Methods and compositions for the treatment and prevention of Staphylococcus a ureus infections |
| 04/22/2004 | US20040077532 Aglyco products and methods of use |
| 04/22/2004 | US20040076986 A gene and/or a protein involved in the prevention or treatment of allergic diseases and dermatitis |
| 04/22/2004 | US20040076985 Reagents which regulate human chemokine-like receptor and reagents which bind to human chemokine-like receptor gene products, useful in preventing, ameliorating, or correcting dysfunctions or diseases including HIV infection, |
| 04/22/2004 | US20040076693 Mixtures of vegetable oils and optionally solubilizers, used for prophylaxis of respiratory system disorders and infections |
| 04/22/2004 | US20040076683 Can be used for treatment of solid or circulating cancerous tumors; exhibit reduced toxicity compared to free drug in solution, exhibit stealth properties with respect to immune system of host to which they are administered |
| 04/22/2004 | US20040076676 Heat-melting polylactic acid having a weight-average molecular weight of 3,000-40,000 at 140-220 degrees C, cooling, pulverizing solidified polylactic acid, adding active materials, compressing powder in mold |
| 04/22/2004 | US20040076643 HIV-encoded chemoattractant |
| 04/22/2004 | US20040076634 An envelope protein, antigens, consisting of amino acid sequances from virus, more potent, protecting from T helper and B cell immunity |
| 04/22/2004 | US20040076633 Genetic vaccines comprising a 1H-imidazo(4,5-c)- 4-amine derivative as an adjuvant, for increasing immune responses in a mammal to the encoded antigen |
| 04/22/2004 | US20040076632 DNA vaccine against feline immunodeficiency virus |
| 04/22/2004 | US20040076631 Treating infections caused by respiratory syncytial virus, transfected eukaryotic cells, isolating human B cells from transfected mouse, use for immunoassay, diagnosis the virus, test kits |
| 04/22/2004 | US20040076625 A fusion proteins comprising self or non-self antigens, is used for treatment and prevention of immunoglobulin E related diseases, gene expression |
| 04/22/2004 | US20040076614 For natural cellular immune defense in humans/animals; for foods/feeds |
| 04/22/2004 | US20040076608 Cytokine uses; compositions; methods |
| 04/22/2004 | US20040076580 For diagnosis/treatment of thrombosis, embolism, atherosclerosis, inflammation or cancer; imaging |
| 04/22/2004 | DE10153346A1 Substituierte Indole Substituted indoles |
| 04/22/2004 | CA2823937A1 Hiv vaccine formulations |
| 04/22/2004 | CA2820949A1 Novel immunogenic proteins of leptospira |
| 04/22/2004 | CA2501939A1 Novel immunogenic proteins of leptospira |
| 04/22/2004 | CA2501352A1 Antimicrobial [3.1.0] bicyclic oxazolidinone derivatives |
| 04/22/2004 | CA2500385A1 Styrylacrylonitrile compounds for inhibition of vascular endothelial growth factor |
| 04/22/2004 | CA2499324A1 S-adenosyl methionine decarboxylase inhibition for the treatment of a herpes simplex virus infection |
| 04/22/2004 | CA2499105A1 Antimicrobial 1-aryl dihydropyridone compounds |
| 04/22/2004 | CA2499081A1 Bispecific molecule comprising an anti-cr1 antibody cross-linked to an antigen-binding antibody fragment |
| 04/22/2004 | CA2498768A1 Methods of treating and preventing neurological symptoms caused by avian reovirus and novel associated characteristics |
| 04/22/2004 | CA2497798A1 Production of peptides in plants as viral coat protein fusions |
| 04/22/2004 | CA2463722A1 Novel k99-5278 substance and a process for production thereof |
| 04/21/2004 | EP1411063A1 Peptide nucleic acids |
| 04/21/2004 | EP1410822A1 Oxa(thia)zolidine compounds, process for preparation thereof and anti-inflammatory agents |
| 04/21/2004 | EP1410805A1 Vaccine against HPV |
| 04/21/2004 | EP1410798A2 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
| 04/21/2004 | EP1410038A2 Assays for identifying modulators of rhomboid polypeptides |
| 04/21/2004 | EP1410018A1 Method for detecting modultators of notch signalling |
| 04/21/2004 | EP1409715A2 Methods and materials relating to neurotrimin-like polypeptides and polynucleotides |
| 04/21/2004 | EP1409701A2 Fluorescently labelled locked nucleic acids |
| 04/21/2004 | EP1409694A1 Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof |
| 04/21/2004 | EP1409692A1 Novel peptides of the respiratory syncytial virus (rsv) g protein and their use in a vaccine |
| 04/21/2004 | EP1409683A2 i HELICOBACTER /i PROTEINS, NUCLEIC ACIDS AND USES THEREOF |
| 04/21/2004 | EP1409682A2 Prevention and treatment of hcv infection employing antibodies directed against conformational epitopes |
| 04/21/2004 | EP1409677A2 Receptors and membrane-associated proteins |
| 04/21/2004 | EP1409673A2 Human leucine-rich repeat containing protein, expressed predominantely in small intestine, hlrrsi1 |
| 04/21/2004 | EP1409670A2 Synthetic double stranded oligonucleotides for targeted inhibition of gene expression |
| 04/21/2004 | EP1409665A2 Method to generate non virulent microorganisms from pathogenic ones trough permanent genetic modification of their biological membrane for vaccine production |
| 04/21/2004 | EP1409655A2 Immunoglobulin superfamily proteins |
| 04/21/2004 | EP1409648A1 New isolated dendritic cells, a process for preparing the same and their use in pharmaceutical compositions |
| 04/21/2004 | EP1409645A1 Probiotic lactobacillus salivarius strains |
| 04/21/2004 | EP1409644A1 Probiotic bifidobacterium strains |
| 04/21/2004 | EP1409550A1 Extracellular messengers |
| 04/21/2004 | EP1409548A2 Ligands to enhance cellular uptake of biomolecules |
| 04/21/2004 | EP1409535A2 Human secreted proteins |
| 04/21/2004 | EP1409532A2 Moringa seed proteins |
| 04/21/2004 | EP1409527A1 Novel human cytomegalovirus (hcmv) cytotoxic t cell epitopes, polyepitopes, compositions comprising same and diagnostic and prophylactic and therapeutic uses therefor |
| 04/21/2004 | EP1409526A2 An inducer of apoptosis |
| 04/21/2004 | EP1409525A2 Human papillomavirus e2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket |
| 04/21/2004 | EP1409492A1 An improved method for preparation of cefuroxime axetil |
| 04/21/2004 | EP1409491A2 Thienopyrimidine-based inhibitors of the src family |
| 04/21/2004 | EP1409487A1 Pteridinones as kinase inhibitors |
| 04/21/2004 | EP1409477A1 Piperidine derivatives as nmda receptor antagonists |
| 04/21/2004 | EP1409466A2 Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis |
| 04/21/2004 | EP1409465A2 Oxazolidinone derivatives as antimicrobials |
| 04/21/2004 | EP1409464A1 Oxazolidinone derivatives as potential antimicrobials |
| 04/21/2004 | EP1409461A1 Novel azole or triazole derivatives, method for preparing same and use thereof as fungicides |
| 04/21/2004 | EP1409077A2 Thermotherapy via targeted delivery of nanoscale magnetic particles |
| 04/21/2004 | EP1409034A1 Topical pharmaceutical formulation |
| 04/21/2004 | EP1409013A1 Vaccines comprising aluminium adjuvants and histidine |
| 04/21/2004 | EP1409012A1 Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein |
| 04/21/2004 | EP1409010A1 Treating endotoxemia and related disorders with probiotics |
| 04/21/2004 | EP1409005A1 Modulators of notch signalling for use in immunotherapy |
| 04/21/2004 | EP1409000A4 Use of agaricus blazei murill to prevent or treat skin and other disorders |
| 04/21/2004 | EP1409000A1 Use of agaricus blazei murill to prevent or treat skin and other disorders |
| 04/21/2004 | EP1408995A1 Modulating serum amyloid a interaction with tanis and agents useful for same |
| 04/21/2004 | EP1408993A2 Halogen compounds for use in medicine |
| 04/21/2004 | EP1408987A2 Tetracycline compounds having target therapeutic activities |
| 04/21/2004 | EP1408986A2 Proteomimetic compounds and methods |
| 04/21/2004 | EP1408984A2 Organo-phosphorous compounds for activating gamma/delta t cells |
| 04/21/2004 | EP1408952A1 Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimer's and related neurodegenerative disorders |
| 04/21/2004 | EP1408947A2 Fumaric acid derivatives as nf-kappab inhibitors |
| 04/21/2004 | EP1408942A1 Methods and clinical devices for the inhibition or prevention of mammalian cell growth |
| 04/21/2004 | EP1408941A2 Pharmaceutical composition and method of using the same |
| 04/21/2004 | EP1408936A2 Pharmaceutical composition |